Search Results - "Bompas, E"

Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO) by Valentin, T, Le Cesne, A, Ray-Coquard, I, Italiano, A, Decanter, G, Bompas, E, Isambert, N, Thariat, J, Linassier, C, Bertucci, F, Bay, J.O, Bellesoeur, A, Penel, N, Le Guellec, S, Filleron, T, Chevreau, C

“…Abstract Background Malignant peripheral nerve sheath tumors (MPNST) are a rare subtype of soft tissue sarcoma. They can arise in irradiated fields, in…”
Get full text

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort by Italiano, A., Bessede, A., Pulido, M., Bompas, E., Piperno-Neumann, S., Chevreau, C., Penel, N., Bertucci, F., Toulmonde, M., Bellera, C., Guegan, J. P., Rey, C., Sautès-Fridman, C., Bougoüin, A., Cantarel, C., Kind, M., Spalato, M., Dadone-Montaudie, B., Le Loarer, F., Blay, J. Y., Fridman, W. H.

“…Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that…”
Get full text

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study by Le Cesne, A., Marec-Berard, P., Blay, J.-Y., Gaspar, N., Bertucci, F., Penel, N., Bompas, E., Cousin, S., Toulmonde, M., Bessede, A., Fridman, W.H., Sautes-Fridman, C., Kind, M., Le Loarer, F., Pulido, M., Italiano, A.

“…There are some lines of evidence suggesting a potential role of immunotherapy for treating patients with osteosarcomas. This was an open-label, multicentre,…”
Get full text

Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group by Toulmonde, M., Bonvalot, S., Méeus, P., Stoeckle, E., Riou, O., Isambert, N., Bompas, E., Jafari, M., Delcambre-Lair, C., Saada, E., Le Cesne, A., Le Péchoux, C., Blay, J.Y., Piperno-Neumann, S., Chevreau, C., Bay, J.O., Brouste, V., Terrier, P., Ranchère-Vince, D., Neuville, A., Italiano, A.

“…Retroperitoneal sarcomas (RPS) are heterogeneous. No previous study has investigated the impact of specialized surgery, evaluated locoregional relapse (LRR),…”
Get full text

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network by Malouf, G.G., Camparo, P., Oudard, S., Schleiermacher, G., Theodore, C., Rustine, A., Dutcher, J., Billemont, B., Rixe, O., Bompas, E., Guillot, A., Boccon-Gibod, L., Couturier, J., Molinié, V., Escudier, B.

“…Xp11 translocation renal cell carcinoma (RCC) is an RCC subtype affecting 15% of RCC patients <45 years. We analyzed the benefit of targeted therapy [vascular…”
Get full text

Advanced chondrosarcomas: role of chemotherapy and survival by Italiano, A., Mir, O., Cioffi, A., Palmerini, E., Piperno-Neumann, S., Perrin, C., Chaigneau, L., Penel, N., Duffaud, F., Kurtz, J.E., Collard, O., Bertucci, F., Bompas, E., Le Cesne, A., Maki, R.G., Ray Coquard, I., Blay, J.Y.

“…There are limited data about the role of chemotherapy in patients with advanced chondrosarcomas. The medical charts of 180 patients with advanced…”
Get full text

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO) by Bompas, E., Le Cesne, A., Tresch-Bruneel, E., Lebellec, L., Laurence, V., Collard, O., Saada-Bouzid, E., Isambert, N., Blay, J.Y., Amela, E.Y., Salas, S., Chevreau, C., Bertucci, F., Italiano, A., Clisant, S., Penel, N.

“…There is no consensual treatment of locally advanced or metastatic chordomas. We conducted a multicenter, open-label, uncontrolled phase II trial of sorafenib…”
Get full text

Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome by Penel, N., Italiano, A., Ray-Coquard, I., Chaigneau, L., Delcambre, C., Robin, Y.M., Bui, B., Bertucci, F., Isambert, N., Cupissol, D., Bompas, E., Bay, J.O., Duffaud, F., Guillemet, C., Blay, J.Y.

“…Angiosarcomas are a rare but aggressive form of soft tissue sarcoma. At metastatic stage, the clinical benefit of therapeutic intervention remains debatable…”
Get full text

A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial by Le Cesne, A., Blay, J.-Y., Cupissol, D., Italiano, A., Delcambre, C., Penel, N., Isambert, N., Chevreau, C., Bompas, E., Bertucci, F., Chaigneau, L., Piperno-Neumann, S., Salas, S., Rios, M., Guillemet, C., Bay, J.-O., Ray-Coquard, I., Haddag, L., Bonastre, J., Kapso, R., Fraslin, A., Bouvet, N., Mir, O., Foulon, S.

“…The French Sarcoma Group assessed the efficacy, safety, and quality of life (QoL) of trabectedin versus best supportive care (BSC) in patients with advanced…”
Get full text

Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients by Honoré, C., Delhorme, J.B., Nassif, E., Faron, M., Ferron, G., Bompas, E., Glehen, O., Italiano, A., Bertucci, F., Orbach, D., Pocard, M., Quenet, F., Blay, J.Y., Carrere, S., Chevreau, C., Mir, O., Le Cesne, A.

“…Despite being associated with a very poor prognosis, long-term survivors across all series of Desmoplastic Small Round Cell Tumor (DSRCT) have been reported…”
Get full text

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial by Adenis, A., Blay, J.-Y., Bui-Nguyen, B., Bouché, O., Bertucci, F., Isambert, N., Bompas, E., Chaigneau, L., Domont, J., Ray-Coquard, I., Blésius, A., Van Tine, B.A., Bulusu, V.R., Dubreuil, P., Mansfield, C.D., Acin, Y., Moussy, A., Hermine, O., Le Cesne, A.

“…Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST). Masitinib…”
Get full text

Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group by Toulmonde, M., Bonvalot, S., Ray-Coquard, I., Stoeckle, E., Riou, O., Isambert, N., Bompas, E., Penel, N., Delcambre-Lair, C., Saada, E., Lecesne, A., Le Péchoux, C., Blay, J.Y., Piperno-Neumann, S., Chevreau, C., Bay, J.O., Brouste, V., Terrier, P., Ranchère-Vince, D., Neuville, A., Italiano, A.

“…Retroperitoneal sarcomas (RPS) are heterogeneous. Advanced stages include unresectable locoregional (LR) disease, abdominal sarcomatosis and distant…”
Get full text

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor by Verspoor, F. G. M., Mastboom, M. J. L., Hannink, G., Maki, R. G., Wagner, A., Bompas, E., Desai, J., Italiano, A., Seddon, B. M., van der Graaf, W. T. A., Blay, J.-Y., Brahmi, M., Eberst, L., Stacchiotti, S., Mir, O., van de Sande, M. A. J., Gelderblom, H., Cassier, P. A.

“…Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often…”
Get full text

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group by Khalifa, J, Ouali, M, Chaltiel, L, Le Guellec, S, Le Cesne, A, Blay, J-Y, Cousin, P, Chaigneau, L, Bompas, E, Piperno-Neumann, S, Bui-Nguyen, B, Rios, M, Delord, J-P, Penel, N, Chevreau, C

“…Advanced malignant solitary fibrous tumors (SFTs) are rare soft-tissue sarcomas with a poor prognosis. Several treatment options have been reported, but with…”
Get full text

A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group by Pautier, P., Floquet, A., Gladieff, L., Bompas, E., Ray-Coquard, I., Piperno-Neumann, S., Selle, F., Guillemet, C., Weber, B., Largillier, R., Bertucci, F., Opinel, P., Duffaud, F., Reynaud-Bougnoux, A., Delcambre, C., Isambert, N., Kerbrat, P., Netter-Pinon, G., Pinto, N., Duvillard, P., Haie-Meder, C., Lhommé, C., Rey, A.

“…There is no proven benefit of adjuvant treatment of uterine sarcoma (US). SARCGYN phase III study compared adjuvant polychemotherapy followed by pelvic…”
Get full text

A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study) by Pautier, P., Penel, N., Ray-Coquard, I., Italiano, A., Bompas, E., Delcambre, C., Bay, J.-O., Bertucci, F., Delaye, J., Chevreau, C., Cupissol, D., Bozec, L., Eymard, J.-C., Saada, E., Isambert, N., Guillemet, C., Rios, M., Piperno-Neumann, S., Chenuc, G., Duffaud, F.

“…Options in second-line therapy after doxorubicin-based chemotherapy for metastatic/advanced leiomyosarcoma include gemcitabine (G), trabectedin and pazopanib…”
Get full text

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival by Italiano, A., Toulmonde, M., Cioffi, A., Penel, N., Isambert, N., Bompas, E., Duffaud, F., Patrikidou, A., Lortal, B., Le Cesne, A., Blay, J.-Y., Maki, R.G., Schwartz, G.K., Antonescu, C.R., Singer, S., Coindre, J.-M., Bui, B.

“…Data regarding the role of systemic therapy in patients with advanced well-differentiated/dedifferentiated liposarcomas (WDLPS/DDLPS) are limited. From 2000 to…”
Get full text

Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG) by Garbay, D., Le Cesne, A., Penel, N., Chevreau, C., Marec-Berard, P., Blay, J.-Y., Debled, M., Isambert, N., Thyss, A., Bompas, E., Collard, O., Salas, S., Coindre, J.-M., Bui, B., Italiano, A.

“…Data regarding the role of chemotherapy (CT) in patients with recurrent and/or unresectable desmoid tumors (DTs) are scarce. Records of patients with DT who…”
Get full text

Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years by Blay, JY, Piperno-Neumann, S., Watson, S., Dufresne, A., Valentin, T., Duffaud, F., Toulmonde, M., Italiano, A., Bertucci, F., Tlemsani, C., Firmin, N., Bompas, E., Perrin, C., Ropars, M., Saada-Bouzid, E., Dubray-Longeras, P., Hervieu, A., Lebbe, C., Gantzer, J., Chaigneau, L., Fiorenza, F., Rios, M., Isambert, N., Soibinet, P., Boudou-Roquette, P., Verret, B., Ferron, G., Ryckewaert, T., Lebellec, L., Brahmi, M., Gouin, F., Meeus, P., Vaz, G., Le Loarer, F., Karanian, M., De Pinieux, G., Ducimetiere, F., Chemin, C., Morelle, M., Le Cesne, A., Penel, N.

“…Epithelioid hemangioendothelioma (EHE) is an ultrarare sarcoma whose natural history and treatment is not well defined. We report on the presentation and…”
Get full text

Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO) by Valentin, T., Fournier, C., Penel, N., Bompas, E., Chaigneau, L., Isambert, N., Chevreau, C.

“…Summary Malignant solitary fibrous tumors are rare soft-tissue sarcomas. They are considered as low-grade malignancies, but may display metastatic potential in…”
Get full text